A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath

Lassa Fever Clinical Trial

Official title:
A Phase 1 Randomized, Double-blinded, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath

Status Active, not recruiting

Clinical Trial Summary

A Phase 1 Randomized, Double-blinded, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Health

Clinical Trial Description

This is a Phase 1 Randomized, Double-blinded, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Health. Approximately 110 participants (88 active product and 22 placebo recipients) will be included in the study Participants will be screened up to 42 days before IP administration and will be followed for 12 months after IP administration. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04794218
Study type	Interventional
Source	International AIDS Vaccine Initiative
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	June 23, 2021
Completion date	March 2024

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT00992693` - Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities	Phase 2
Completed	`NCT04285034` - Cardiovascular Function and Ribavirin PK/PD in Lassa Fever in Lassa Fever
Completed	`NCT03805984` - Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers	Phase 1
Recruiting	`NCT05868733` - A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa	Phase 2
Terminated	`NCT03889106` - Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever
Completed	`NCT04907682` - Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever	Phase 2
Not yet recruiting	`NCT06212336` - ISTH/ANRS 0409s INTEGRATE Lassa Fever Study	Phase 2/Phase 3
Completed	`NCT04093076` - Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana	Phase 1
Not yet recruiting	`NCT06222723` - LAssa Fever Adjunct Treatment With DEXamethasone	Phase 2
Recruiting	`NCT03655561` - Lassa Fever Clinical Course and Prognostic Factors in Nigeria